Vigorous Mixing May Effect Blood Results
|
By LabMedica International staff writers Posted on 21 Feb 2013 |
|
The effect of tube mixing techniques on the quality of diagnostic blood specimens collected in vacuum tube systems by venipuncture has been evaluated.
The accurate mixing of blood in tubes with anticoagulant- or clot activator additives is essential for their effectiveness and may influence the reliability of test results and thereby affect the diagnostic outcome, the follow-up, and the therapeutic management of patients.
Clinical biochemists at the University of Verona (Italy) collected blood from 100 volunteers for routine coagulation, immunochemistry, and hematological testing from April 1, 2012, to May 1, 2012. The blood was put into six vacuum tubes: two 3.6 mL vacuum tubes containing 0.4 mL of buffered sodium citrate; two 3.5 mL vacuum tubes with clot activator and gel separator; and two 3.0 mL vacuum tubes containing dipotassium ethylenediaminetetraacetic acid (K2EDTA). All vacuum tubes, each of one additive type were processed through two different procedures.
The standard procedure was blood specimens in K2EDTA- or sodium citrate-vacuum tubes were gently inverted five times whereas the specimens in tubes with clot activator and gel separator were gently inverted ten times. The second procedure consisted of all the blood specimens were shaken up vigorously during three to five seconds independently of the additive type inside the tubes.
Routine hematology, clinical chemistry, and immunochemistry and coagulation tests were performed. The results of the investigation for all the parameters showed that no significant differences were detected between the standard procedures versus the vigorous mix. Only a visual alteration with the presence of foam on the top was shown by all the tubes mixed vigorously before centrifugation. The serum tubes from vigorous mixing procedure shows a “blood ring” on the tube top after stopper removal.
The vacuum tubes used were manufactured by Terumo Europe (Heverlee, Belgium). The authors concluded that primary blood tubes vigorous mixing does not promote laboratory variability and suggest that similar evaluation should be done using other brands of vacuum tubes by each laboratory manager. The study was published in the February 2013 issue of the journal Clinical Biochemistry.
Related Links:
University of Verona
Terumo Europe
The accurate mixing of blood in tubes with anticoagulant- or clot activator additives is essential for their effectiveness and may influence the reliability of test results and thereby affect the diagnostic outcome, the follow-up, and the therapeutic management of patients.
Clinical biochemists at the University of Verona (Italy) collected blood from 100 volunteers for routine coagulation, immunochemistry, and hematological testing from April 1, 2012, to May 1, 2012. The blood was put into six vacuum tubes: two 3.6 mL vacuum tubes containing 0.4 mL of buffered sodium citrate; two 3.5 mL vacuum tubes with clot activator and gel separator; and two 3.0 mL vacuum tubes containing dipotassium ethylenediaminetetraacetic acid (K2EDTA). All vacuum tubes, each of one additive type were processed through two different procedures.
The standard procedure was blood specimens in K2EDTA- or sodium citrate-vacuum tubes were gently inverted five times whereas the specimens in tubes with clot activator and gel separator were gently inverted ten times. The second procedure consisted of all the blood specimens were shaken up vigorously during three to five seconds independently of the additive type inside the tubes.
Routine hematology, clinical chemistry, and immunochemistry and coagulation tests were performed. The results of the investigation for all the parameters showed that no significant differences were detected between the standard procedures versus the vigorous mix. Only a visual alteration with the presence of foam on the top was shown by all the tubes mixed vigorously before centrifugation. The serum tubes from vigorous mixing procedure shows a “blood ring” on the tube top after stopper removal.
The vacuum tubes used were manufactured by Terumo Europe (Heverlee, Belgium). The authors concluded that primary blood tubes vigorous mixing does not promote laboratory variability and suggest that similar evaluation should be done using other brands of vacuum tubes by each laboratory manager. The study was published in the February 2013 issue of the journal Clinical Biochemistry.
Related Links:
University of Verona
Terumo Europe
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
RNA Blood Test Detects Cancers and Resistance to Treatment
A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. This innovative test, created by researchers... Read more
IL-6 Outperforms Traditional Tests for Early Sepsis Detection
Sepsis, a severe and life-threatening condition caused by the immune system’s exaggerated response to infection, remains a major cause of death globally, responsible for approximately 11 million fatalities... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read more
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
